(function(){ var content_array=["

關于勃林格殷格翰<\/b> <\/p> \n

勃林格殷格翰是全球領先的生物制藥企業，布局人用藥品、動物保健兩大業務領域。公司研發投入位居行業前列，致力于研究突破性療法，解決巨大未滿足的醫療需求，從而幫助改善或延長生命。自1885年成立以來，勃林格殷格翰一直是獨立的家族企業，始終著眼長遠發展，將可持續發展理念貫穿全價值鏈。公司在全球有超過5.35萬名員工，服務逾130個市場，致力于打造一個更健康、更可持續、更公平的未來。更多詳情，請訪問：www.boehringer-ingelheim.cn<\/a>， www.boehringer-ingelheim.com<\/a><\/p> \n

References<\/b> <\/p> \n

\n \n \n \n
<noscript id="kgssg"><option id="kgssg"></option></noscript><optgroup id="kgssg"><wbr id="kgssg"></wbr></optgroup><optgroup id="kgssg"></optgroup>
<optgroup id="kgssg"><div id="kgssg"></div></optgroup>
<center id="kgssg"><div id="kgssg"></div></center>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

[1] Richeldi L, et al. (2025) Nerandomilast in patients with idiopathic pulmonary fibrosis. In: NEJM. 2025.<\/span> <\/p>

[2] Maher TM, et al. (2025) Nerandomilast in patients with progressive pulmonary fibrosis. In: NEJM. 2025.<\/span> <\/p>

[3] Twisk JWR et al. (1998). Tracking of lung function parameters and the longitudinal relationship with lifestyle. European Respiratory Journal.<\/i> 12(3):627–634.<\/span> <\/p>

[4] Sauleda J, et al. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med Sci (Basel). 2018 Nov 29;6(4):110. doi: 10.3390\/medsci6040110. PMID: 30501130; PMCID: PMC6313500.<\/span> <\/p>

[5] European Lung Foundation (2023) IPF - Idiopathic Pulmonary Fibrosis. Accessed April 2025. Available at: https:\/\/europeanlung.org\/en\/information-hub\/factsheets\/ipf-idiopathic-pulmonary-fibrosis\/<\/a>. <\/span> <\/p>

[6] Podolanczuk AJ, Fernández Peréz ER. Identification, course, and management of progressive pulmonary fibrosis. Am J Manag Care. 2024 Oct;30(7 Suppl):S122-S130. doi: 10.37765\/ajmc.2024.89634. PMID: 39495032.<\/span> <\/p>

[7] Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021 Jul 7;22(1):197. doi: 10.1186\/s12931-021-01791-z. PMID: 34233665; PMCID: PMC8261998.<\/span> <\/p>

[8] Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The Burden of Progressive-Fibrosing Interstitial Lung Diseases. Front Med (Lausanne). 2022 Feb 1;9:799912. Doi: 10.3389\/fmed.2022.799912. PMID: 35178411; PMCID: PMC8843847. Assuming a world population of 8bn<\/span> <\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p> \n\"\""]; $("#dvExtra").html(content_array[0]);})();